Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

Obesity, guidelines for medical management of OA and, 1535, 1541
Obituaries
Ropes, Marian W., 866
Stevens, Mary Betty, 444
Occult microbial pathogens, autoimmune disease induction by, 458
Occupation, morbidity in SLE and, 267
Occupational factors, knee OA in athletes, 539
Occupational therapists, guidelines for medical management of OA and, 1535, 1541
Ocular involvement, IL-1α polymorphism in JRA and, 221
Office-based ultrasonography, diagnostic use of, in Baker's cyst of knee joint, 859
Office visits, costs of drugs in RA and, 318
Oligoarthritis, pediatric Lyme arthritis in Europe, 361
Oligoarthropathy, undifferentiated seronegative, Chlamydia DNA in SF in, 1005
Oligoclonal T cells, T cell receptors in RA and, 577, 1242
Oligodeoxyribonucleotides, Chlamydia DNA in SF in reactive arthritis and oligoarthropathy and, 1005
Oligohybridization, to study HLA-B39 in AS and pauciarticular JRA, 1672
Oligonucleotides
in RA, 1242, 1754
T cell receptors and, 1242
typing with, to study HRES-1 antibodies in SLE and overlap syndromes, 1660
Oligosaccharides, carbohydrate in RA immune complexes and, 744
[gq]3 fatty acids, high-dose fish oil in RA and, 1107
Omeprazole
NSAID, gastrointestinal tract and, 5
tenidap and, in experimental canine OA, 1290
134-amino acid region, 181-amino acid fragment α1(I)78CBN of type I collagen, Yersinia enterocolitica adhesin YadA and, 1283
Opioid analgesics, guidelines for medical management of OA and, 1535, 1541
Opportunistic infection in RA,
chimeric monoclonal anti-CD4 antibody, MTX and, 1581
leflunomide in, 1595
Oral analgesics, guidelines for medical management of OA and, 1535, 1541
Oral cyclophosphamide, malignancy and, in RA, 1120
Oral gold, cost of, in RA, 318
Oral GP-1-515, antiinflammatory effects of adenosine regulators and, 1040
Oral MTX
liver biopsy after, in RA, 1194
shelf-life of parenteral MTX and, 575
Oral omeprazole, tenidap and, in experimental canine OA, 1290
Oral 2-chlorodeoxyadenosine, in psoriatic arthritis, 1604
Oral type II collagen, in antigen-induced arthritis, 1092
Organ graft rejection, immunosuppressive drugs during pregnancy and, 1722
Organ involvement
clodronate-containing liposomes, macrophages and, in rat adjuvant arthritis, 1777
guidelines for clinical trials in SSc and, 351
peripheral lymphoid, autoimmune disease induction by microbial pathogens and, 458
in SLE, 633, 1475
Organ-specific autoimmunity, 301
Orthopedic prosthesis, failed, loosening of revision total hip replacement in RA, 1315
Orthopedic surgery and orthopedic surgeons
guidelines for medical management of OA and, 1535, 1541
student's perspective on RA and, 315
Osp A, Osp B, Osp C, in Lyme borreliosis, 565
Osseus hydatid disease, in chronic monarthritis, 1338
Osteoarthritis (OA)
canine, 525, 1290
cathepsin and collagenase in, 976
chondrocytes in, 413, 1304
early, aggrecan and type II collagen genes in, 420
end-stage, cardiovascular health and fitness in, 799
experimental, 201, 420, 525, 1290
familial, COL2A1 gene in, 999
gender and surgery in, 448
guidelines for medical management of, 1535, 1541
hip, 907, 1535
hypothalamic-pituitary-adrenal effects of NSAID in, 923
insulin-like growth factor 1 in, 413
knee, 78, 420, 539, 660, 760, 1134, 1500, 1541
lesions in, 1290
matrix metalloproteinase inhibitors in, 574
measuring relevant change in rheumatologic clinical trials and, 1027
monoclonal antibodies in detection of biochemical markers of, 655
NSAID and hypothalamic-pituitary-adrenal axis in, 723
proteoglycans in, 525, 660
RA and, 384, 477, 486, 642, 678, 969, 976
SF in, Arg-Gly-Asp (RGD) peptide and IL-1 in chondrocyte matrix metalloproteinase synthesis and, 1304
tenidap in, 1290
Osteocalcin
bone sialoprotein in RA SF and, 82
bone turnover and bone mass after estrogen and, 292
scintigraphic abnormalities, bone turnover and, in OA, 78
steroids, bone metabolism and, in postmenopausal RA bone metabolism, 902
Osteomyelitis, chronic
hypothalamic-pituitary-adrenal effects of NSAID in, 723
IL-1 receptor antagonist in RA and, 642
Osteophytes, in OA, 907, 1290, 1500
Osteoporosis, in RA, 806
Osteoporotic Fractures Research Group, bone mineral density in hip OA and, 907
Outcome measures
in Clinical Trials (OMERACT), 1568
in dehydroepiandrosterone in SLE, 1826
draft guidelines for drugs in JRA clinical trials and, 715
in MTX and prednisone in Wegener's granulomatosis, 608
in RA, 727, 819, 1097, 1568, 1595, 1799, 1807
in Spanish patients, 1429
in SSc, guidelines for clinical trials and, 351
in walking velocity in elderly, 343
Outcome studies
continuing medical education in rheumatic diseases for primary care physicians, 533
evaluative laboratory testing and, 1555
HLA type in MCTD, 259
hyaluronic acid and disease progression in OA, 760
pain in JRA, 1142
survival in SLE, 274
Outpatient care
joint and connective tissue ultrasonography in, 736
in RA, 318, 1754
rheumatology education and, 451
walking velocity in elderly and, 343
Overlap syndromes, HRES-1 antibodies in, 1660
Oxidation, lipoprotein, SSc and, 1060
Oxidized low-density lipoprotein, cross-reactivity of anticardiolipin autoantibodies with, 1382
Oxycodone, guidelines for medical management of OA and, 1535
Oxygen consumption, cardiovascular health and fitness in end-stage OA and, 799
Oxygen-derived free radicals, in TGFβ1 in hyaluronan synthesis in synovial lining cells, 669
Oxyhemoglobin, lipoxin A4, nitric oxide and, in polymorphonuclear neutrophil vascular cytotoxicity, 768